246 related articles for article (PubMed ID: 26708118)
1. Economic Impact of Oritavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Emergency Department or Observation Setting: Cost Savings Associated with Avoidable Hospitalizations.
Lodise TP; Fan W; Sulham KA
Clin Ther; 2016 Jan; 38(1):136-48. PubMed ID: 26708118
[TBL] [Abstract][Full Text] [Related]
2. Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
Jensen IS; Lodise TP; Fan W; Wu C; Cyr PL; Nicolau DP; DuFour S; Sulham KA
Clin Drug Investig; 2016 Feb; 36(2):157-68. PubMed ID: 26692006
[TBL] [Abstract][Full Text] [Related]
3. Assessing the economic value of avoiding hospital admissions by shifting the management of gram+ acute bacterial skin and skin-structure infections to an outpatient care setting.
Ektare V; Khachatryan A; Xue M; Dunne M; Johnson K; Stephens J
J Med Econ; 2015; 18(12):1092-101. PubMed ID: 26368787
[TBL] [Abstract][Full Text] [Related]
4. Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
Jensen IS; Wu E; Fan W; Lodise TP; Nicolau DP; Dufour S; Cyr PL; Sulham KA
J Manag Care Spec Pharm; 2016 Jun; 22(6):752-64. PubMed ID: 27231802
[TBL] [Abstract][Full Text] [Related]
5. Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment.
Lane S; Johnston K; Sulham KA; Syed I; Pollack CV; Holland T; Nathwani D
Clin Ther; 2016 Mar; 38(3):531-44; quiz 544.e1-9. PubMed ID: 26874786
[TBL] [Abstract][Full Text] [Related]
6. Ceftaroline fosamil use in hospitalized patients with acute bacterial skin and skin structure infections: Budget impact analysis from a hospital perspective.
Huang X; Beresford E; Lodise T; Friedland HD
Am J Health Syst Pharm; 2013 Jun; 70(12):1057-64. PubMed ID: 23719884
[TBL] [Abstract][Full Text] [Related]
7. Modeling operational quality metrics and costs of long-acting antibiotics for acute bacterial skin and skin structure infection treatment in the emergency department.
Keyloun KR; Lofgren E; Hebert S
J Med Econ; 2019 Jul; 22(7):652-661. PubMed ID: 30838908
[No Abstract] [Full Text] [Related]
8. Modeling economic implications of alternative treatment strategies for acute bacterial skin and skin structure infections.
Revankar N; Ward AJ; Pelligra CG; Kongnakorn T; Fan W; LaPensee KT
J Med Econ; 2014 Oct; 17(10):730-40. PubMed ID: 25019580
[TBL] [Abstract][Full Text] [Related]
9. Potential Cost-Savings with Once-Daily Aminomethylcycline Antibiotic versus Vancomycin in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections.
LaPensee K; Lodise T
Am Health Drug Benefits; 2018 Dec; 11(9):449-459. PubMed ID: 30746017
[TBL] [Abstract][Full Text] [Related]
10. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W;
Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective.
Zinzi D; Vlachaki I; Falla E; Mantopoulos T; Nathwani D
Eur J Health Econ; 2022 Nov; 23(8):1371-1381. PubMed ID: 35113269
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States.
Keyloun KR; Weber DJ; Gardstein BM; Berger A; Gillard P; Ganz ML
Hosp Pract (1995); 2018 Dec; 46(5):278-286. PubMed ID: 30067108
[No Abstract] [Full Text] [Related]
13. Oritavancin for acute bacterial skin and skin structure infections.
Messina JA; Fowler VG; Corey GR
Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
[TBL] [Abstract][Full Text] [Related]
14. Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital.
Saddler K; Zhang J; Sul J; Patel P; Castro-Lainez M; Stevens ML; Kosler S; Lowery E; Sierra-Hoffman M
PLoS One; 2021; 16(3):e0248129. PubMed ID: 33735185
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of antibiotics for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a systematic review and network meta-analysis.
Thom H; Thompson JC; Scott DA; Halfpenny N; Sulham K; Corey GR
Curr Med Res Opin; 2015 Aug; 31(8):1539-51. PubMed ID: 26038985
[TBL] [Abstract][Full Text] [Related]
16. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
Agarwal R; Bartsch SM; Kelly BJ; Prewitt M; Liu Y; Chen Y; Umscheid CA
Clin Microbiol Infect; 2018 Apr; 24(4):361-368. PubMed ID: 28882727
[TBL] [Abstract][Full Text] [Related]
17. Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.
Wu G; Truong J; Lee S; Elnadoury O; Kuan W; Abraham T; Wu A; Liu M
Expert Rev Anti Infect Ther; 2015 Apr; 13(4):409-16. PubMed ID: 25661747
[TBL] [Abstract][Full Text] [Related]
18. Oritavancin: a review in acute bacterial skin and skin structure infections.
Syed YY; Scott LJ
Drugs; 2015 Nov; 75(16):1891-902. PubMed ID: 26464319
[TBL] [Abstract][Full Text] [Related]
19. Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study.
Anastasio PJ; Wolthoff P; Galli A; Fan W
Infect Dis Ther; 2017 Mar; 6(1):115-128. PubMed ID: 28078655
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
